newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

  • Bezuclastinib demonstrated a 65% objective response rate (ORR) per mIWG criteria and an 81% ORR per PPR criteria in patients with advanced systemic mastocytosis (AdvSM).
  • 91% of patients achieved a ≥50% reduction in variant allele frequency, while 89% achieved a ≥50% reduction in bone marrow mast cells or clearance of aggregates.
  • The drug showed a favorable safety profile with frequent but manageable treatment-related adverse events including hair color change (31%), neutropenia (31%), altered taste (28%), thrombocytopenia (25%), and ALT/AST elevations (21%).
  • Clinical data indicated durable activity with a 12-month progression-free survival rate of 79% and a 12-month overall survival rate of 87%.
  • APEX New Drug Application (NDA) submission is scheduled for June 2026.
  • Cogent Biosciences plans to launch bezuclastinib later in 2026 for systemic mastocytosis and GIST following FDA approval.
  • Updated data from the APEX trial involving 81 AdvSM patients will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm.
  • Pathobiology results included rapid reductions in aberrant CD25/CD30 expression, normalization of mast cell morphology, and improvement in myelofibrosis.
  • Approximately one-third of treated patients achieved undetectable levels of KIT D816V variant allele frequency.
  • Active Expanded Access Programs (EAPs) are established for U.S. patients with systemic mastocytosis or GIST who meet specific disease criteria.